Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate

NCT ID: NCT05607342

Last Updated: 2024-02-21

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: EARLY_PHASE1
• Total Enrollment: 1 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-01-03
• Study Completion Date: 2023-11-06

Brief Summary

To evaluate the effect of Osanetant on testosterone levels in men with prostate cancer within 28 days of therapy.

Detailed Description

Primary:

To evaluate the effect of Osanetant on testosterone levels in men with prostate cancer within 28 days of therapy.

Secondary:

• To evaluate the effect Osanetant on pituitary hormones (LH/FSH) and estrogen within 28 days of therapy.
• To evaluate the effect of Osanetant on PSA levels after 28 days (approximately 4 weeks) of therapy.

Conditions

Prostate Adenocarcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Pilot Trial: Osanetant 28 Days

Pilot Trial: A single dose level (200mg twice daily, oral) will be provided for men with prostate cancer undergoing curative intent surgery. Men will undergo serum testing at baseline, days 2, 3, 7, 14, and 28 as well as 6 weeks post-treatment in order to evaluate efficacy. All men enrolled will be subject to the same study procedures and assessments, regardless of completion of the study protocol, and analysis will occur via intent-to-treat principles.

Group Type: EXPERIMENTAL

Osanetant

Intervention Type: DRUG

To evaluate the effect of Osanetant on the testosterone levels.

Interventions

Osanetant

To evaluate the effect of Osanetant on the testosterone levels.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent
• Males ≥ 18 years
• Histologic diagnosis of adenocarcinoma of the prostate (PCa)
• Planned radical prostatectomy within the study period
• Testosterone >150ng/ml
• Adequate organ function, defined as follows: Result Date

• Leukocytes >1.5K/UL
• Absolute Neutrophil Count >1.5K/UL
• NOTE: Patients with established diagnosis of benign neutropenia are eligible to participate with ANC between 1000-1500 if in the opinion of treating physician the trial treatment does not pose excessive risk of infection to the patient.
• Platelets >100K/UL
• Hemoglobin ≥ 9 g/dL
• Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault equation
• Total bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ 1 x ULN
• Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x ULN unless liver metastases are present, in which case they must be ≤ 5 x ULN
• Men with partners of child-bearing potential must agree to practice sexual abstinence or to use the forms of contraception listed in Child-Bearing Potential/Pregnancy section for the duration of study participation. Men of child-bearing potential must not father a child or donate sperm while receiving investigational treatment. Following treatment (standard of care prostatectomy) there is no further child-bearing potential.

Exclusion Criteria

• Current or recent (within 6 months) use of testosterone/estrogen modulating agents (leuprolide, degarelix, bicalutamide, enzalutamide, apalutamide, darolutamide, abiraterone, systemic ketoconazole, tamoxifen, etc)
• Current use of CYP3A4 inhibitors
• Subjects using the following medications within 2 weeks prior to first dosing (or within 5 times the half-life of that medication, whichever is longer) will be excluded from the study:

• Inhibitors of CYP3A4 (including but not limited to macrolide antibiotics, HIV protease inhibitor, azole antifungal drugs, cyclosporine, calcium channel inhibitor, cimetidine)
• Inducers of CYP3A4 (including but not limited to rifampicin, carbamazepine, efavirenz, bosentan, modafinil, St. John's Wort), Medications with narrow therapeutic index that are metabolized CYP3A4 and/or CYP2D6 are not allowed from screening until up to 5 half-lives after last dose of Osanetant is administered.
• Cognitive impairment (defined as the presence of diagnosed dementia)
• Impaired renal function: Cr >1.8
• Medical history of osteoporosis
• Current systemic corticosteroid, long-term opioid, spironolactone, or eplerenone use
• Has a known allergic reaction to any excipient contained in the study drug formulation
• Active Grade 3 (per the NCI CTCAE, Version 5.0) or higher viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study treatment.
• Active COVID-19 infection
• Any history of underlying liver disorder, including hepatitis (see below)
• Any evidence of acute or chronic hepatitis B or C on screening testing
• Elevation of any or all liver enzymes (ALT, AST, total bilirubin) above the upper limit of normal (ULN) at baseline testing prior to enrollment
• A family history of hepatitis or currently living with a person who has been given a diagnosis of hepatitis
• A history of or currently working as a sex worker
• A history of or currently using intravenous (IV) drugs
• A self-reported history of alcoholic dependency or abuse
• A history of or current diagnosis of cardiovascular disease including heart failure, coronary artery disease, uncontrolled hypertension, uncontrolled diabetes; arrhythmias (or history of), or clinically relevant ECG abnormalities at baseline

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

University of Kansas Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

The University of Kansas Cancer Center, Westwood Campus

Kansas City, Kansas, United States

Countries

United States

Other Identifiers

STUDY00148767

Identifier Type: -

Identifier Source: org_study_id